Eduovisual
Female Reproductive & Breast
Mastitis and breast abscess: diagnosis and management
— Lactational (puerperal) mastitis: 2–6 weeks postpartum peak; affects 10–20% of breastfeeding women; usually unilateral, wedge-shaped erythema.
— Non-lactational mastitis: includes periductal mastitis (smokers, subareolar), idiopathic granulomatous mastitis, and chronic/recurrent subareolar abscess (Zuska disease).
— Lactating woman with focal breast pain, warmth, erythema, fever ≥38.5°C, myalgias, flu-like symptoms within first 12 weeks postpartum.
— Non-lactating woman 30–50s with subareolar tenderness, nipple discharge, or recurrent abscess — particularly a current smoker.
— Any breast inflammation in a postmenopausal woman without lactation history → must exclude inflammatory breast cancer (IBC).
— Lactational: milk stasis → bacterial overgrowth (most commonly Staphylococcus aureus, including MRSA) entering through cracked nipple.
— Periductal: squamous metaplasia of ducts (driven by smoking) → keratin plugging → ductal rupture → mixed flora infection (anaerobes, S. aureus, Bacteroides, Peptostreptococcus).
— Family medicine clerkship favorite: ambulatory diagnosis without imaging in classic lactational cases.
— High-stakes pitfall: missing IBC masquerading as "mastitis that won't resolve."
Board pearl: Any "mastitis" that fails to improve after 48–72 hours of appropriate antibiotics in a non-lactating or postmenopausal patient mandates diagnostic mammography + ultrasound + skin punch biopsy to rule out inflammatory breast cancer — do not keep cycling antibiotics.
— 3-week postpartum primipara, breastfeeding, presents with 24–48 h of unilateral breast pain, a tender firm wedge of erythema in the upper outer quadrant, fever 38.8°C, chills, fatigue.
— Often preceded by engorgement, missed feeds, oversupply, tight bra, or a recent return to work changing feeding schedule.
— Cracked or fissured nipple is the typical portal of entry; ask about latch difficulties.
— Persistent symptoms >48–72 h despite antibiotics, palpable fluctuant mass, focal worsening pain after initial improvement, sometimes spontaneous purulent drainage.
— Non-lactating woman, 30s–40s, smoker, recurrent subareolar abscesses, nipple retraction, chronic mammary duct fistula draining at areolar margin.
— Parous woman within 5 years of last pregnancy, often Hispanic or Asian descent, firm peripheral mass mimicking carcinoma; biopsy required.
— Postmenopausal, no lactation, peau d'orange, rapid skin thickening over days–weeks, painless adenopathy, unilateral nipple inversion of new onset.
— Feeding frequency, pump use, recent weaning, nipple trauma.
— Smoking, prior abscess, prior breast surgery, piercings.
— Diabetes, HIV, immunosuppression (predispose to abscess and atypical organisms).
— Drug history: bromocriptine, antipsychotics (galactorrhea-related ductal stasis).
Step 3 management: In the outpatient encounter, always document breastfeeding goals at the visit — continued nursing or pumping from the affected breast is therapeutic, not contraindicated, and stopping breastfeeding worsens mastitis by promoting stasis. Frame counseling around this single high-yield point before prescribing.
— Wedge-shaped erythema radiating from nipple is classic lactational pattern.
— Look for nipple fissures, cracks, candidal changes (shiny pink/peeling), inverted nipple (new inversion is a red flag).
— Skin changes: peau d'orange, dimpling, ulceration → think IBC or advanced abscess.
— Asymmetry, visible bulge suggesting underlying collection.
— Warm, tender, indurated segment; assess for a discrete fluctuant mass (suggests abscess).
— Examine all four quadrants and axillary tail; check both breasts for comparison.
— Reactive axillary lymphadenopathy common and not alarming in mastitis; fixed, matted, or supraclavicular nodes are concerning.
— Temperature, HR, BP, RR, SpO₂. Most mastitis is afebrile-to-low-grade; high fever with rigors, tachycardia >120, hypotension, or altered mental status → assess for sepsis.
— qSOFA ≥2 or SIRS criteria warrant IV antibiotics and admission.
— Mild–moderate: localized erythema, low-grade fever, no fluctuance, hemodynamically stable, tolerating PO → outpatient PO antibiotics.
— Severe / complicated: fluctuance, abscess >3 cm, immunocompromise, failure of outpatient therapy 48 h, systemic toxicity → imaging + drainage ± IV antibiotics.
— Subareolar fluctuant mass + nipple retraction + smoker → periductal mastitis/Zuska.
— Firm peripheral lump without overlying erythema in young parous woman → consider granulomatous mastitis.
Key distinction: A wedge-shaped erythema with focal tenderness in a lactating woman is mastitis until proven otherwise; a diffuse erythematous, edematous breast with peau d'orange and no fluctuance, in any woman, is inflammatory breast cancer until biopsy proves otherwise. Do not anchor on infection.
— No labs or imaging required if classic presentation, no fluctuance, and patient is non-toxic.
— Empiric antibiotics started at the visit.
— Systemic toxicity, failure of 48 h of antibiotics, immunocompromise, diabetes, or recurrent disease.
— CBC with differential (leukocytosis with left shift), CRP, basic metabolic panel.
— Blood cultures only if sepsis or admission.
— Milk culture is not routine but consider in hospital-acquired, severe, recurrent, or antibiotic-refractory cases (per ABM Protocol #36).
— Indication: suspected abscess (fluctuance, failure to improve, palpable mass), or to guide aspiration.
— Findings: hypoechoic or anechoic fluid collection with posterior acoustic enhancement, irregular walls, internal debris.
— Ultrasound also enables needle aspiration, the diagnostic and therapeutic procedure of choice.
— Not first-line in acute mastitis (painful, low yield).
— Mandatory in non-lactational women ≥30 years with mastitis that doesn't resolve in 1–2 weeks, or any suspicion of malignancy — order diagnostic (not screening) mammogram + targeted ultrasound.
— Send for Gram stain, aerobic and anaerobic culture, sensitivities.
— If abscess content is bloody, atypical, or cytology suggestive → send for cytology; suspicious findings prompt core biopsy.
— Indicated if peau d'orange, suspected IBC, or non-resolving inflammation despite drainage.
CCS pearl: For a hospitalized septic patient with breast abscess, your CCS order set is: CBC, CMP, lactate, blood cultures ×2, breast ultrasound, IV vancomycin, IV access, NPO if OR likely, surgery consult. Move clock forward only after cultures are drawn before first antibiotic dose.
— 18-gauge needle, drain to dryness; repeat every 2–3 days as needed.
— Successful in 80–90% of abscesses <3 cm; avoids incision and preserves breastfeeding.
— Send fluid for Gram stain, culture (aerobic + anaerobic), and cytology if any concern for malignancy.
— Indicated for non-resolving "mastitis," suspicion of IBC, suspicious imaging (BI-RADS 4–5), or atypical cytology.
— Granulomatous mastitis is a histologic diagnosis: non-caseating granulomas centered on lobules, neutrophilic microabscesses.
— Rule out TB, sarcoid, fungal disease, Corynebacterium kroppenstedtii (cystic neutrophilic granulomatous mastitis).
— Confirms or excludes inflammatory breast cancer by demonstrating dermal lymphatic invasion.
— Mandatory when erythema involves >1/3 of breast skin and fails antibiotics.
— Reserved for complex/multiloculated abscess, atypical infections, suspected fistula, or when ultrasound is inadequate.
— Helpful in idiopathic granulomatous mastitis to map disease extent.
— Persistent infection: request anaerobic culture, AFB, fungal culture, and Corynebacterium species (requires lipid-supplemented media).
— Consider HIV testing in recurrent or unusual abscesses.
— Occasionally used to delineate ductal fistula in Zuska disease before surgical excision.
— TB, sarcoid, fungal, foreign body, Corynebacterium, Wegener (GPA), idiopathic.
Board pearl: A recurrent subareolar abscess in a smoker with a mammary duct fistula = Zuska disease; definitive cure requires total duct excision after acute infection is controlled — antibiotics and drainage alone produce relapse rates above 50%.
— Symptomatic relief: NSAIDs (ibuprofen), acetaminophen, warm compresses before feeds, cold compresses after.
— Continue breastfeeding/pumping from affected breast every 2–3 h (key teaching point).
— Improve latch (lactation consultant referral), avoid tight bras.
— Empiric PO antibiotics × 10–14 days (see chunk 7).
— Reassess in 48–72 h; expect symptomatic improvement.
— Breast ultrasound; if abscess confirmed → needle aspiration under US guidance.
— Broaden antibiotics to cover MRSA if not already.
— Send aspirate cultures, tailor therapy.
— Surgical consultation for incision and drainage (I&D) under local or general anesthesia.
— IV antibiotics, admit.
— Smoking cessation counseling.
— Imaging workup (mammogram + US ± MRI).
— Surgical referral for definitive duct excision after acute infection settles.
— Biopsy first; treatment is conservative (observation, NSAIDs, sometimes corticosteroids or methotrexate); avoid aggressive surgery, which worsens disease.
— Diabetes, obesity, smoking, HIV, prior breast surgery/radiation, MRSA colonization, delayed presentation >72 h.
Step 3 management: In an outpatient, non-toxic lactating woman with classic mastitis, your single highest-yield order set is: dicloxacillin or cephalexin × 10–14 days, ibuprofen, lactation consult referral, 48-hour follow-up call, and explicit instruction to continue breastfeeding from both breasts. Don't stop nursing.
— Dicloxacillin 500 mg PO QID × 10–14 days, or
— Cephalexin 500 mg PO QID × 10–14 days (preferred if mild penicillin allergy).
— Both compatible with breastfeeding.
— Local MRSA prevalence >10–15%, prior MRSA, abscess, severe disease, IVDU, recent hospitalization, or failure of beta-lactam at 48 h.
— TMP-SMX DS 1 tab PO BID — avoid in first month postpartum or in infants <2 months, with G6PD deficiency, or hyperbilirubinemia (risk of kernicterus).
— Clindamycin 300–450 mg PO QID — safer in early postpartum, covers MRSA + anaerobes (good for periductal mastitis).
— Doxycycline: avoid in breastfeeding if prolonged use, though short courses (<21 d) generally acceptable.
— Vancomycin 15–20 mg/kg IV q8–12h (target AUC 400–600) for MRSA risk or sepsis.
— Alternative: linezolid, daptomycin (not for pneumonia, but fine for skin/soft tissue).
— Add piperacillin-tazobactam if mixed flora or non-lactational abscess (anaerobes).
— Amoxicillin-clavulanate 875/125 mg PO BID, or clindamycin, to cover anaerobes (Bacteroides, Peptostreptococcus) and S. aureus.
— Uncomplicated: 10–14 days.
— Abscess with drainage: 7–14 days post-drainage based on response.
— Ibuprofen 400–600 mg q6h PRN; acetaminophen.
— Lecithin or therapeutic ultrasound for recurrent ductal plugging.
Board pearl: Avoid TMP-SMX in the first month postpartum if the infant is breastfeeding (risk of kernicterus in neonates with hyperbilirubinemia or G6PD deficiency) — choose clindamycin for MRSA coverage in that window.
— Indicated for abscesses <5 cm, unilocular, with intact overlying skin.
— Technique: sterile prep, 1% lidocaine local, 18-G needle under ultrasound, aspirate to dryness, irrigate with saline if desired.
— Repeat every 2–3 days until no further fluid (often 1–3 sessions).
— Cure rates 80–90%; preserves breastfeeding; minimal scarring.
— Send aspirate for Gram stain, aerobic/anaerobic culture, ± cytology.
— Abscess >5 cm, multiloculated, thinned overlying skin or impending rupture, failure of needle aspiration ×2–3, or necrotic tissue.
— Performed in OR (general anesthesia) for large/deep collections; smaller can be done bedside with local.
— Make incision in dependent position along Langer lines, away from areola when possible, to preserve cosmesis and milk ducts.
— Pack loosely; allow healing by secondary intention; daily dressing changes.
— After acute infection controlled, perform total subareolar duct excision (Hadfield procedure) to remove diseased ducts and prevent recurrence.
— Smoking cessation is essential — recurrence is the rule without it.
— Avoid aggressive surgical resection — wound complications and recurrence common.
— Medical management with observation, topical/systemic corticosteroids (prednisone 0.5–1 mg/kg/day taper), or methotrexate for refractory cases.
— Continue feeding from affected breast even after I&D unless incision precludes latch — then pump and discard if drainage contaminates milk; resume direct feeding once incision is sealed.
CCS pearl: For a large lactational abscess, your CCS sequence: NPO, IV fluids, IV vancomycin, breast US, surgery consult for I&D, post-op continue antibiotics, lactation consult, pain control, follow-up in clinic 1 week. Advance the clock in 2-hour increments around the OR window.
— Mastitis without lactation in this group is inflammatory breast cancer until proven otherwise.
— Always order diagnostic mammogram + targeted US + skin punch biopsy even before antibiotics if peau d'orange or rapid progression.
— Comorbidities (diabetes, obesity) increase abscess risk; expect more Streptococcus, anaerobes, and gram-negatives.
— Higher risk of abscess, polymicrobial infection, MRSA, delayed healing.
— Glycemic optimization is part of treatment; check A1c if not recent.
— Lower threshold for imaging and surgical consultation.
— Consider atypical organisms: TB, fungal, Nocardia, atypical mycobacteria.
— Broader cultures, possible biopsy, infectious disease consultation.
— Cephalexin: reduce dose if CrCl <30 (e.g., 250–500 mg q8–12h).
— TMP-SMX: reduce by 50% if CrCl 15–30; avoid <15 unless dialyzed.
— Vancomycin: dose by AUC; monitor trough/AUC, especially with concurrent nephrotoxins; check baseline creatinine.
— Clindamycin: no renal adjustment needed — useful in CKD.
— Clindamycin and TMP-SMX undergo hepatic metabolism — caution in cirrhosis; clindamycin usually still preferred for MRSA in liver disease at standard doses with monitoring.
— Dicloxacillin/cephalexin are renally cleared and well tolerated in liver disease.
— Hold or reverse anticoagulation before incision and drainage when feasible; needle aspiration acceptable on therapeutic anticoagulation in many cases — coordinate with surgery.
Key distinction: In a 70-year-old woman with diffuse breast erythema and edema, the workup is mammogram + ultrasound + skin punch biopsy, not an empiric antibiotic trial — Step 3 will punish you for "treat and see" in this demographic.
— Antibiotic safety: cephalexin (Cat B), dicloxacillin (Cat B), clindamycin (Cat B) all acceptable.
— Avoid TMP-SMX in first trimester (folate antagonist → neural tube defects) and near term (kernicterus risk).
— Avoid tetracyclines (fetal tooth/bone) and fluoroquinolones (cartilage concerns).
— Imaging: ultrasound is safe; mammography can be performed with abdominal shielding if needed.
— Continue breastfeeding — milk is safe for the infant even from the infected breast in lactational mastitis; stasis worsens disease.
— If pus drains directly into milk (e.g., open I&D site over areola), pump and discard from that breast temporarily, but maintain supply.
— Engage lactation consultant for latch correction, scheduled feeds, and pump optimization.
— Address nipple trauma: lanolin, hydrogel pads, topical mupirocin for fissures.
— Screen for postpartum depression — pain and feeding difficulty increase risk.
— Rare; presents in first 2–6 weeks of life, more often in term infants, slight female predominance.
— S. aureus most common; treat with IV antibiotics (nafcillin or vancomycin) and surgical drainage; admit.
— Avoid manipulation of breast bud (risk of permanent breast tissue damage in girls).
— Consider trauma, piercings, eczema, atopic dermatitis as predisposing factors.
— Same antibiotic principles as adults; counsel on hygiene around piercings.
— Safe: cephalexin, dicloxacillin, clindamycin, amoxicillin-clavulanate.
— Cautious: TMP-SMX (avoid <1 month, G6PD, hyperbilirubinemia).
— Avoid prolonged: doxycycline, fluoroquinolones, metronidazole high-dose.
Step 3 management: For postpartum mastitis, your discharge bundle is antibiotic + ibuprofen + lactation consult + warm compresses + continued nursing + 48-h follow-up + postpartum depression screen (EPDS or PHQ-9).
— Breast abscess: most common complication of delayed/inadequate treatment (3–11% of lactational mastitis).
— Mammary duct fistula: chronic communication between subareolar duct and skin; hallmark of Zuska disease.
— Skin necrosis and ulceration: from neglected or large abscesses, especially in diabetics.
— Chronic recurrent abscess: particularly in smokers and patients with retained duct disease.
— Scarring, cosmetic deformity, nipple inversion: more common after surgical I&D than needle aspiration.
— Premature weaning (often patient-driven from pain or misinformation).
— Decreased milk supply in affected breast.
— Recurrent plugged ducts.
— Sepsis and septic shock — uncommon but possible, especially with MRSA or in immunocompromised.
— Toxic shock syndrome if S. aureus producing TSST-1.
— Bacteremia, endocarditis — rare but described.
— Metastatic infection: vertebral osteomyelitis, septic arthritis (from S. aureus bacteremia).
— Missed inflammatory breast cancer: every cycle of empiric antibiotics without biopsy in non-lactating women is a missed staging opportunity; IBC is T4d at diagnosis (stage III at best).
— Missed granulomatous mastitis treated as infection: prolonged morbidity, unnecessary surgery.
— Clindamycin → C. difficile colitis; counsel on diarrhea.
— TMP-SMX → SJS/TEN, hyperkalemia, kernicterus in neonates.
— Vancomycin → AKI, infusion reaction (red man syndrome), ototoxicity.
— Postpartum depression exacerbation, breastfeeding guilt, body image distress.
Board pearl: Persistent or recurrent breast abscess in a non-lactating woman = rule out malignancy and TB (especially in immigrants from endemic regions); send aspirate for AFB stain and culture in addition to routine bacteriology.
— Non-toxic, hemodynamically stable, tolerates PO.
— No abscess, or small abscess (<3 cm) drainable in clinic.
— Reliable follow-up in 48–72 h.
— No significant immunocompromise.
— Systemic toxicity, persistent high fever, inability to tolerate PO, dehydration.
— Large or multiloculated abscess requiring OR drainage.
— Failed outpatient therapy with worsening disease.
— Severe pain not controlled with PO analgesia.
— Immunocompromised host with progressing infection.
— Significant comorbidity (poorly controlled diabetes, pregnancy with concerns).
— Septic shock (lactate >2, vasopressor requirement, hypotension despite 30 mL/kg crystalloid).
— Respiratory failure (rare — think TSS or necrotizing infection).
— Necrotizing soft tissue infection (extremely rare in breast but possible) → emergent surgical debridement.
— Concern for toxic shock syndrome: fever, hypotension, diffuse macular rash, multi-organ dysfunction.
— General/breast surgery: any abscess requiring drainage beyond bedside, recurrent disease, suspected ductal pathology.
— Lactation consultant: every lactational case — improves outcomes and breastfeeding continuation.
— Infectious disease: refractory, atypical organisms, immunocompromised, suspected TB or fungal.
— Breast oncology / radiology: any concern for IBC, non-resolving non-lactational mastitis.
— Rheumatology: granulomatous mastitis for steroid/methotrexate management.
— Discharge when afebrile 24 h, tolerating PO, abscess drained or controlled, pain managed, follow-up arranged.
CCS pearl: For septic breast abscess, the time-critical orders within the first hour are blood cultures ×2, lactate, IV broad-spectrum antibiotics (vancomycin + piperacillin-tazobactam), 30 mL/kg crystalloid bolus, surgery consult, ICU evaluation — advance the clock to assess response at 3 and 6 hours.
— Bilateral, diffuse, day 3–5 postpartum, no fever (or low-grade <38.4°C), no focal erythema.
— Treatment: frequent feeding, expression, cold compresses; resolves in 24–48 h.
— Localized tender lump, no systemic symptoms, no significant erythema; relieves with massage and feeding.
— Can progress to mastitis if persistent >24–48 h.
— Milk-filled cyst, painless or mildly tender, may enlarge gradually, no fever.
— Diagnosed by US; aspiration if symptomatic.
— Burning, shooting pain after feeds, shiny pink nipples, thrush in infant.
— Treat both mother (topical miconazole/nystatin or oral fluconazole) and infant (oral nystatin).
— Subareolar, recurrent, smoker; covered in chunk 6/8.
— Firm mass mimicking cancer; biopsy-confirmed; treat medically.
— Chronic indolent mass, sinus tracts, often immigrants from endemic areas; AFB on biopsy.
— Post-trauma or post-surgical, firm painless mass, oil cyst on imaging; mimics malignancy on mammogram (calcifications).
— Superficial thrombophlebitis of breast veins; tender palpable cord, no abscess; self-limited.
— Diffuse erythema without underlying parenchymal infection; treat with cephalexin.
— Inframammary fold abscesses with sinus tracts; chronic recurrent.
Key distinction: Engorgement is bilateral and afebrile; mastitis is unilateral, focal, and febrile; abscess is unilateral with a fluctuant mass. A simple triad to anchor your differential within the lactating patient.
— Rapid (<6 months) onset of breast erythema involving ≥1/3 of breast, peau d'orange, edema, warmth, often without a discrete mass.
— Age usually >40, but can occur in younger women.
— Diagnosis: diagnostic mammogram + targeted ultrasound + skin punch biopsy demonstrating dermal lymphatic invasion.
— Staged T4d at diagnosis (clinical stage IIIB minimum); treatment is neoadjuvant chemotherapy → mastectomy + axillary dissection → radiation ± targeted therapy.
— Mass with overlying ulceration or fixation; biopsy.
— Eczematous, scaly, sometimes ulcerated nipple/areola, often unilateral; biopsy shows intraepithelial adenocarcinoma cells.
— Frequently associated with underlying DCIS or invasive carcinoma.
— Painless mass, sometimes bilateral; biopsy.
— Melanoma, lung, ovarian; usually known primary.
— Granulomatous breast involvement; systemic features and biopsy distinguish from idiopathic granulomatous mastitis.
— History of prior radiation; usually within months of treatment.
— Pruritic, well-demarcated, related to topical exposure (nipple creams, detergents).
— Long-standing type 1 diabetes, firm painless mass; biopsy benign lymphocytic lobulitis.
— Rapidly growing painless mass; not inflammatory but can be confused if large.
Board pearl: Any "mastitis" in a non-lactating woman that has not resolved after one full course of appropriate antibiotics (10–14 days) warrants tissue diagnosis. Sending the patient home with a second antibiotic course is the wrong answer on Step 3.
— Effective latch (lactation consultant referral) — most modifiable risk factor.
— Frequent on-demand feeding (8–12 times/day); avoid long gaps.
— Alternate starting breast at each feeding.
— Empty breast completely; pump if infant doesn't transfer adequately.
— Treat nipple cracks promptly (lanolin, hydrogel, topical antibiotic if open lesion).
— Avoid tight bras, underwires, sleeping prone (compression promotes stasis).
— Manage oversupply (block feeding, lecithin for recurrent plugs).
— Smoking cessation — single most important intervention for periductal mastitis; quitlines, varenicline, NRT, counseling.
— Treat diabetes aggressively (A1c <7%).
— Address obesity, hidradenitis, eczema as appropriate.
— Lactational: complete antibiotic course, finish drainage, ensure breastfeeding continues, follow-up imaging only if persistent mass.
— Periductal/Zuska: refer to breast surgery for elective duct excision once acute infection resolves.
— Granulomatous: long-term rheumatology/breast surgery follow-up; steroids may require months.
— Use the encounter to confirm age-appropriate mammography: USPSTF 2024 recommends biennial mammography ages 40–74.
— Women at high risk (BRCA, prior chest radiation, ≥20% lifetime risk) → annual mammogram + MRI, earlier start.
— Bring up to date: Tdap (especially postpartum), influenza, COVID, HPV if eligible.
— Record resolution of inflammation, ensure no residual mass; any palpable lump persisting >2–4 weeks post-treatment → image.
Step 3 management: At the post-mastitis follow-up, your checklist is: symptom resolution, palpation for residual mass, breastfeeding status, smoking cessation reinforcement, mammography update, postpartum depression screen, contraception counseling.
— 48–72 h phone or in-person check after starting antibiotics — confirm symptomatic improvement; if not improving, escalate (ultrasound, MRSA coverage, drainage).
— 1 week in-person visit to assess resolution and wound (if drained).
— 2–4 weeks to confirm full clinical resolution and palpate for residual mass.
— Persistent mass at 4–6 weeks → imaging + biopsy.
— Pain, erythema extent, fever curve, drainage character/volume, breastfeeding continuation, milk supply.
— In hospitalized patients: vital signs, CBC, CRP trend, wound assessment daily.
— Daily dressing changes with saline or dilute Dakin solution; packing reduction as cavity closes.
— Healing by secondary intention; expect 2–4 weeks.
— Watch for retained loculations or new collection.
— Continue feeding/pumping every 2–3 h.
— Start feeds on affected breast first (stronger suckling drains effectively).
— Massage toward nipple during feeds.
— Refer to IBCLC (board-certified lactation consultant) — measurable impact on outcomes.
— Ibuprofen scheduled (not PRN) for first 48 h; acetaminophen adjunct.
— Sleep, hydration, nutrition counseling.
— Screen for postpartum depression at every encounter using EPDS or PHQ-9.
— Return if fever >38.5°C persists >48 h after antibiotics, worsening pain, new fluctuance, spreading erythema, systemic symptoms.
— Schedule dedicated visit; use 5 A's (Ask, Advise, Assess, Assist, Arrange); pharmacotherapy as needed.
Board pearl: Failure to improve at 48–72 hours is the universal Step 3 trigger to obtain breast ultrasound and broaden to MRSA coverage — do not wait a full week to reassess a febrile mastitis patient.
— Document risks of needle aspiration and I&D: bleeding, infection, scarring, recurrence, milk fistula (lactating patients), need for repeat procedures, possible damage to ducts affecting future lactation.
— Discuss alternatives, including expectant management with antibiotics in select small abscesses.
— Some patients will request to wean during mastitis; counsel that continued feeding is preferred and safe for the infant but ultimately respect informed maternal autonomy.
— Do not coerce; document discussion.
— Recurrent breast injury, unusual bruising, or inconsistent history → screen for intimate partner violence (IPV); offer resources and safety planning. IPV screening is recommended at every postpartum visit (USPSTF B).
— Suspected child abuse if neonatal/infant injuries observed during exam → mandatory report per state law.
— Postpartum patients are at high risk for being lost to follow-up; ensure a scheduled 48-h call, named clinician, and direct contact number before discharge.
— Closed-loop communication of culture results — if MRSA grows after discharge on cephalexin, document call to patient and prescription change.
— Hand-off between OB, family medicine, surgery, and lactation must be explicit.
— Disparities in breastfeeding support, access to lactation consultants, and timely imaging exist; advocate for early referral.
— Use interpreters for non-English-speaking patients; consent must be in the patient's language.
— Always document that IBC was considered and excluded in non-lactating mastitis, including imaging and biopsy when indicated. This is both medicolegally and clinically protective.
— Use LactMed (NIH) database to verify drug compatibility — counsel patients explicitly.
Step 3 management: When a non-lactating woman with persistent "mastitis" declines biopsy after two failed antibiotic courses, your next step is shared decision-making with documented discussion of inflammatory breast cancer risk, written acknowledgment, and a defined short-interval re-evaluation plan — never just refill antibiotics.
Board pearl: Memorize the trio "continue breastfeeding, dicloxacillin/cephalexin × 10–14 days, ultrasound if not improved in 48–72 hours" — it answers ~70% of mastitis questions on Step 3.
— 28-year-old, postpartum week 3, breastfeeding, wedge erythema, fever 38.8°C, no fluctuance.
— Answer: dicloxacillin or cephalexin; continue breastfeeding; ibuprofen; lactation consult.
— Distractor: "discontinue breastfeeding" — wrong.
— Same patient now on day 4 of cephalexin, palpable fluctuant mass.
— Answer: breast ultrasound + needle aspiration; expand to MRSA coverage (clindamycin or TMP-SMX if >1 month postpartum).
— 58-year-old postmenopausal woman, no lactation, 6-week history of breast erythema and edema with peau d'orange, no abscess on US, "treated with two courses of antibiotics."
— Answer: diagnostic mammogram + ultrasound + skin punch biopsy — NOT another antibiotic.
— 40-year-old smoker with recurrent subareolar abscesses and a draining sinus at areolar margin.
— Answer: drain acute infection, antibiotics covering anaerobes (amoxicillin-clavulanate or clindamycin), then total duct excision + smoking cessation.
— 32-year-old Hispanic woman, 2 years postpartum, firm peripheral mass, biopsy = non-caseating granulomas, AFB negative.
— Answer: observation or corticosteroids; avoid aggressive surgical resection.
— Septic-appearing postpartum woman, hypotensive, large abscess.
— Answer: IV vancomycin + surgical I&D + fluids + admit.
— Day 4 postpartum, bilateral fullness, low-grade temp, no focal erythema.
— Answer: frequent feeding, expression — no antibiotics.
— Burning pain after feeds, shiny pink nipples, infant with white plaques.
— Answer: topical antifungal to mother + oral nystatin to infant.
Key distinction: Step 3 loves the non-resolving mastitis in a non-lactating woman stem to test whether you'll order biopsy versus another antibiotic — biopsy is always the correct answer when antibiotics have failed.
Mastitis is a clinical diagnosis treated empirically with dicloxacillin or cephalexin while continuing breastfeeding; failure to improve in 48–72 hours mandates ultrasound for abscess drainage, and any non-lactating or postmenopausal woman with non-resolving inflammation requires diagnostic mammography, ultrasound, and skin punch biopsy to rule out inflammatory breast cancer.
Step 3 management: Tie every mastitis encounter to longitudinal care — confirm age-appropriate mammography, screen for postpartum depression and intimate partner violence, optimize smoking cessation and diabetes control, and close the loop with a scheduled 48–72 hour reassessment so no patient is lost between visits or between disciplines (family medicine, OB, surgery, and lactation).